# Panelists Debate Europe’s Biotech Funding Prospects for 2027 at London Event

Panelists at Fierce Biotech’s London Life Sciences Week event discussed whether Europe can compete with the United States and China in biopharma investment next year. The session, held in London, focused on the possibility that 2027 could become “Europe’s year to shine” in biotech funding.

The discussion centered on Europe’s ability to attract and sustain biopharma investment against the strong pull of the U.S. and Chinese markets. Panelists examined the ingredients needed for Europe to pull its weight in the global biotech funding landscape.

**Context**

Biotech funding determines which regions can advance drug development, medical devices, and animal health innovations. Europe has historically trailed the U.S. in venture capital and public market support for life sciences. A shift in investment patterns could affect where new therapies are discovered and manufactured, influencing global access to medicines and veterinary treatments.

Source: [original report](https://www.fiercebiotech.com/biotech/fierce-biotech-llsw-its-europes-year-shine-all-ingredients-are-here-biotech-funding)